🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  2. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  3. NDV-01 (sustained-release gemcitabine-docetaxel)

    RELMADA THERAPEUTICS, INC.

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 3 small molecule active

    2 trials

  4. NDV-01 (sustained-release gemcitabine-docetaxel)

    RELMADA THERAPEUTICS, INC.

    Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)

    phase 3 small molecule terminated

    1 trial

  5. NEORAL® Soft Gelatin Capsules 100mg, Methotrexate 2.5 mg Tablets, Zilbrysq 16.6 mg solution for injection in pre-filled syringe, Prednisolone 5mg Tablets, Azathioprine Tablets 50mg Oprisine, Privigen 100 mg/ml solution for infusion, Soliris 300 mg concentrate for solution for infusion, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 50mg, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 10mg, Methotrexate 2.5 mg Tablets, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 25mg, K

    Kyverna Therapeutics

    Generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  6. NI-501; emapalumab, NI-501; emapalumab

    Swedish Orphan Biovitrum Pty Ltd

    Macrophage activation syndrome (MAS) in the context of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult onset Still's disease (AOSD). MAS in the context of pediatric and adult Systemic Lupus Erythematosus (SLE).

    phase 3 small molecule active

    1 trial

  7. NICOPASS 1,5 mg SANS SUCRE MENTHE FRAICHEUR, pastille édulcorée à l'aspartam et à l’acésulfame potassique, V0018 Placebo

    Pierre Fabre Medicament

    Cessation of smoking

    phase 3 small molecule active

    1 trial

  8. NILOTINIB, ASCIMINIB HYDROCHLORIDE, NILOTINIB, NILOTINIB

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  9. NIVOLUMAB, Bemarituzumab, OXALIPLATIN, FOLINIC ACID, Placebo for AMG 552, CAPECITABINE , FLUOROURACIL

    Amgen

    Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression

    phase 3 small molecule active

    1 trial

  10. NIVOLUMAB, GEMCITABINE, TEPMETKO 225 mg film-coated tablets, PACLITAXEL, DOCETAXEL, ATEZOLIZUMAB, BEVACIZUMAB, PEMBROLIZUMAB, VINORELBINE, PEMETREXED

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  11. NKTR-181 BID tablets

    Nektar Therapeutics UK Limited

    Low Back Pain

    phase 3 small molecule completed

    2 trials

  12. NNC0487-0111 B 10146, Placebo, NNC0487-0111 B 10141, NNC0487-0111 B 10142, NNC0487-0111 B 10143, NNC0487-0111 B 10145, NNC0487-0111 B 10144

    NovoThirteen

    Overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial

  13. NUBEQA 300 mg film-coated tablets, Placebo to BAY1841788 film-coated tablet 300 mg

    Ningbo Cancer Hospital

    Localised Very High-Risk Cancer of the Prostate

    phase 3 small molecule active

    1 trial

  14. NaCl 0,9 % B. Braun, solution injectable, Depo-Medrone 40 mg/ml Suspension for Injection.

    Disc Medicine

    Cluster headache

    phase 3 small molecule active

    1 trial

  15. NaCl 0.9%, PREDNISONE ARROW 20 mg, comprimé sécable, METHYLPREDNISOLONE , Placebo de prednisone ARW 20 mg - Hydrogénophosphate de calcium dihydraté (94%) Stéarate de magnésium (1%) Amidon de maïs Lycatab C (5%), Glucose 5%

    Pari Pharma GmbH

    Erythema multiforme (EM) in its severe form managed at the hospital

    phase 3 small molecule active

    1 trial

  16. Nab-paclitaxel 80 mg/m^2

    CORCEPT THERAPEUTICS INC

    Ovarian Neoplasm

    phase 3 small molecule active

    1 trial

  17. Nabilone

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 3 small molecule completed

    1 trial

  18. Nabilone

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 3 small molecule active

    1 trial

  19. Nabiximols

    Jazz Pharmaceuticals Ireland Limited

    Post-Traumatic Stress Disorder

    phase 3 small molecule terminated

    1 trial

  20. Nabiximols

    Jazz Pharmaceuticals Ireland Limited

    Pain

    phase 3 small molecule completed

    3 trials

  21. Nabiximols

    Jazz Pharmaceuticals Ireland Limited

    Multiple Sclerosis (MS)

    phase 3 small molecule terminated

    1 trial

  22. Nabiximols

    Jazz Pharmaceuticals Ireland Limited

    Spasticity With Multiple Sclerosis

    phase 3 small molecule terminated

    1 trial

  23. Nabiximols

    Jazz Pharmaceuticals Ireland Limited

    Spasticity in Participants With Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  24. Nacubactam, Imipenem/Cilastatin Kabi 500 mg/500 mg Pulver zur Herstellung einer Infusionslösung, Cefepim PANPHARMA 2 g Pulver zur Herstellung einer Injektions- bzw. Infusionslösung, AZACTAM 1 g, poudre et solution pour usage parentéral

    Lacuna Pharma Pty Ltd

    Complicated urinary tract infection (cUTI) and acute uncomplicated pyelonephritis (AP)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources